Yang‐Min Ning

2.6k total citations
33 papers, 1.7k citations indexed

About

Yang‐Min Ning is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Yang‐Min Ning has authored 33 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 11 papers in Surgery. Recurrent topics in Yang‐Min Ning's work include Prostate Cancer Treatment and Research (14 papers), Bladder and Urothelial Cancer Treatments (11 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Yang‐Min Ning is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Bladder and Urothelial Cancer Treatments (11 papers) and Cancer Immunotherapy and Biomarkers (8 papers). Yang‐Min Ning collaborates with scholars based in United States and Netherlands. Yang‐Min Ning's co-authors include Edwin R. Sánchez, Richard Pazdur, Robert Justice, Patricia Keegan, William L. Dahut, Ann T. Farrell, William D. Figg, James L. Gulley, John R. Johnson and Ravi A. Madan and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Yang‐Min Ning

33 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yang‐Min Ning United States 17 594 566 445 287 223 33 1.7k
Laura Zanotti Italy 27 546 0.9× 527 0.9× 341 0.8× 150 0.5× 352 1.6× 76 1.9k
Nancy Lewis United States 29 875 1.5× 1.5k 2.7× 811 1.8× 516 1.8× 354 1.6× 62 2.9k
Paola Muzi Italy 23 661 1.1× 405 0.7× 467 1.0× 103 0.4× 254 1.1× 52 1.5k
Hiroyuki Konaka Japan 22 475 0.8× 305 0.5× 447 1.0× 58 0.2× 157 0.7× 81 1.4k
Anne M. Noonan United States 27 561 0.9× 1.3k 2.2× 396 0.9× 354 1.2× 360 1.6× 117 2.1k
David Oram United Kingdom 28 436 0.7× 486 0.9× 212 0.5× 159 0.6× 296 1.3× 64 3.3k
Roohi Ismail‐Khan United States 23 898 1.5× 1.1k 1.9× 702 1.6× 268 0.9× 332 1.5× 60 2.4k
Werner Rittgen Germany 24 843 1.4× 1.0k 1.8× 278 0.6× 458 1.6× 260 1.2× 38 2.0k
Miles C. Andrews Australia 18 591 1.0× 1.6k 2.8× 360 0.8× 1.1k 3.8× 167 0.7× 52 2.4k
Kimio Ushijima Japan 28 756 1.3× 850 1.5× 357 0.8× 336 1.2× 313 1.4× 159 3.2k

Countries citing papers authored by Yang‐Min Ning

Since Specialization
Citations

This map shows the geographic impact of Yang‐Min Ning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yang‐Min Ning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yang‐Min Ning more than expected).

Fields of papers citing papers by Yang‐Min Ning

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yang‐Min Ning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yang‐Min Ning. The network helps show where Yang‐Min Ning may publish in the future.

Co-authorship network of co-authors of Yang‐Min Ning

This figure shows the co-authorship network connecting the top 25 collaborators of Yang‐Min Ning. A scholar is included among the top collaborators of Yang‐Min Ning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yang‐Min Ning. Yang‐Min Ning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kronstein, Phillip D., et al.. (2022). Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency. Therapeutic Innovation & Regulatory Science. 56(5). 753–764. 7 indexed citations
2.
Ning, Yang‐Min, et al.. (2022). Comparison of Good Clinical Practice Inspection Processes for Marketing Applications Between the United States Food and Drug Administration and the European Medicines Agency. Therapeutic Innovation & Regulatory Science. 57(1). 79–85. 1 indexed citations
3.
Girardi, Daniel M., Scot A. Niglio, Amir Mortazavi, et al.. (2020). Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.. Journal of Clinical Oncology. 38(15_suppl). 5037–5037. 2 indexed citations
4.
Niglio, Scot A., Daniel M. Girardi, Amir Mortazavi, et al.. (2020). Ipilimumab challenge/re-challenge in metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors treated with cabozantinib+nivolumab (CaboNivo) or cabozantinib+nivolumab+ipilimumab (CaboNivoIpi).. Journal of Clinical Oncology. 38(15_suppl). 5039–5039. 3 indexed citations
5.
Weinstock, Chana, V. Ellen Maher, Laura L. Fernandes, et al.. (2019). An FDA analysis of the association between adverse events and outcome in patients with urothelial cancer receiving a programmed death protein 1 or programmed death ligand 1 (anti-PD-1/L1) antibody.. Journal of Clinical Oncology. 37(15_suppl). 4549–4549. 1 indexed citations
6.
7.
8.
Apolo, Andrea B., Amir Mortazavi, Mark N. Stein, et al.. (2017). A phase I study of cabozantinib plus nivolumab (CaboNivo) and ipilimumab (CaboNivoIpi) in patients (pts) with refractory metastatic urothelial carcinoma (mUC) and other genitourinary (GU) tumors.. Journal of Clinical Oncology. 35(6_suppl). 293–293. 36 indexed citations
9.
Ning, Yang‐Min & V. Ellen Maher. (2015). Food and Drug Administration process for development and approval of drugs and radiopharmaceuticals: Treatments in urologic oncology. Urologic Oncology Seminars and Original Investigations. 33(3). 137–142. 1 indexed citations
10.
Ning, Yang‐Min, Michael H. Brave, V. Ellen Maher, et al.. (2015). U.S. Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. The Oncologist. 20(8). 960–966. 35 indexed citations
11.
Theoret, Marc R., Yang‐Min Ning, Jenny J. Zhang, et al.. (2011). The Risks and Benefits of 5α-Reductase Inhibitors for Prostate-Cancer Prevention. New England Journal of Medicine. 365(2). 97–99. 98 indexed citations
12.
Johnson, John R., Yang‐Min Ning, Ann T. Farrell, et al.. (2011). Accelerated Approval of Oncology Products: The Food and Drug Administration Experience. JNCI Journal of the National Cancer Institute. 103(8). 636–644. 155 indexed citations
13.
Stein, Wilfred D., James L. Gulley, Jeff Schlom, et al.. (2010). Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy. Clinical Cancer Research. 17(4). 907–917. 201 indexed citations
14.
Ning, Yang‐Min, William D. Figg, & William L. Dahut. (2009). Reversal of Docetaxel Resistance With Bevacizumab and Thalidomide. Clinical Genitourinary Cancer. 7(2). E37–E38. 5 indexed citations
15.
Aragon‐Ching, Jeanny B., Yang‐Min Ning, Clara C. Chen, et al.. (2009). Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents. Cancer Investigation. 27(2). 221–226. 106 indexed citations
16.
Aragon‐Ching, Jeanny B., Yang‐Min Ning, & William L. Dahut. (2008). Acute aortic dissection in a hypertensive patient with prostate cancer undergoing chemotherapy containing bevacizumab. Acta Oncologica. 47(8). 1600–1601. 15 indexed citations
17.
18.
Ning, Yang‐Min, et al.. (2002). A New First Step in Activation of Steroid Receptors. Journal of Biological Chemistry. 277(7). 4597–4600. 344 indexed citations
19.
Ning, Yang‐Min & Edwin R. Sánchez. (1995). Stabilization in vitro of the untransformed glucocorticoid receptor complex of S49 lymphocytes by the immunophilin ligand FK506. The Journal of Steroid Biochemistry and Molecular Biology. 52(2). 187–194. 28 indexed citations
20.
Hutchison, Kevin A., Lawrence C. Scherrer, Michael J. Czar, et al.. (1993). FK506 binding to the 56-kilodalton immunophilin (hsp56) in the glucocorticoid receptor heterocomplex has no effect on receptor folding or function. Biochemistry. 32(15). 3953–3957. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laura Zanotti Breakdown of academic impact, for papers by Nancy Lewis Breakdown of academic impact, for papers by Paola Muzi Breakdown of academic impact, for papers by Hiroyuki Konaka Breakdown of academic impact, for papers by Anne M. Noonan Breakdown of academic impact, for papers by David Oram Breakdown of academic impact, for papers by Roohi Ismail‐Khan Breakdown of academic impact, for papers by Werner Rittgen Breakdown of academic impact, for papers by Miles C. Andrews Breakdown of academic impact, for papers by Kimio Ushijima
Rankless by CCL
2026